LO9A Stock Overview
A commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
VBI Vaccines Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.57 |
52 Week High | US$1.40 |
52 Week Low | US$0.57 |
Beta | 2.17 |
11 Month Change | 0% |
3 Month Change | -6.51% |
1 Year Change | -51.36% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -99.47% |
Recent News & Updates
Recent updates
Shareholder Returns
LO9A | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 2.8% | 0.9% |
1Y | -51.4% | -14.6% | 5.7% |
Return vs Industry: LO9A underperformed the German Biotechs industry which returned -14.6% over the past year.
Return vs Market: LO9A underperformed the German Market which returned 5.7% over the past year.
Price Volatility
LO9A volatility | |
---|---|
LO9A Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 6.5% |
Market Average Movement | 4.7% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: LO9A's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine LO9A's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 135 | Jeff Baxter | www.vbivaccines.com |
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus.
VBI Vaccines Inc. Fundamentals Summary
LO9A fundamental statistics | |
---|---|
Market cap | €19.42m |
Earnings (TTM) | -€77.48m |
Revenue (TTM) | €8.68m |
2.2x
P/S Ratio-0.3x
P/E RatioIs LO9A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LO9A income statement (TTM) | |
---|---|
Revenue | US$9.41m |
Cost of Revenue | US$11.67m |
Gross Profit | -US$2.26m |
Other Expenses | US$81.73m |
Earnings | -US$83.99m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.93 |
Gross Margin | -24.03% |
Net Profit Margin | -892.47% |
Debt/Equity Ratio | -891.6% |
How did LO9A perform over the long term?
See historical performance and comparison